Vanda Pharmaceuticals, Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company primarily focused on the development and commercialization of innovative therapies to address unmet medical needs. The company’s core objective is to discover, develop, and deliver novel treatments for patients suffering from a range of medical disorders, particularly within the areas of central nervous system disorders and other areas of high clinical demand. Vanda Pharmaceuticals is recognized for its emphasis on addressing sleep-related disorders, major depressive disorder, schizophrenia, and other chronic disorders. Its flagship product includes the sleep therapy drug, Hetlioz, which is used to treat Non-24-Hour Sleep-Wake Disorder, primarily affecting individuals who are blind, and delayed sleep phase disorder. Another prominent medication developed by Vanda is Fanapt, an atypical antipsychotic used to manage schizophrenia. With its headquarters in Washington, D.C., Vanda Pharmaceuticals plays a significant role in the biopharmaceutical market by leveraging its expertise in neuropsychiatry. The company continually invests in research and development to enhance its pipeline and expand its influence in developing drugs that address critical gaps in the healthcare sector.